Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line
immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse …

Autophagy plays a vital role in sustaining cellular homeostasis and its alterations have been
implicated in the etiology of many diseases. Drugs development targeting autophagy began …

Patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL), ineligible
for or relapsing after autologous stem‐cell transplant or chimeric antigen‐receptor T‐cell …

Simple Summary Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy,
but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage …

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous non-Hodgkin
lymphoma that is extremely aggressive and has an intermediate to high malignancy. Some …

Diffuse large B-cell lymphoma (DLBCL) encompasses a wide variety of disease states that
have to date been subgrouped and characterized based on immunohistochemical methods …

Simple Summary Since the identification of a large variety of biomarkers in B cell
malignancies as being driving factors for tumor progression and patient prognosis, their …

Cancer treatment remains a significant challenge due to issues such as acquired resistance
to conventional therapies and the occurrence of adverse treatment-related toxicities. In …

Follicular lymphoma (FL) is the most common low-grade lymphoma, and although nodal FL
is highly responsive to treatment, the majority of patients relapse repeatedly, and the …